USA flag logo/image

An Official Website of the United States Government

N-Methanocarbathymidine (N-MCT) for the treatment of herpes and pox virus…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R44AI078540
Solicitation Year:
2012
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
NANDN SCIENTIFIC, INC.
10521 ALLOWAY DRIVE POTOMAC, MD -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: N-Methanocarbathymidine (N-MCT) for the treatment of herpes and pox virus infecti
Agency: HHS
Contract: 2R44AI078540-03A1
Award Amount: $2,879,710.00
 

Abstract:

DESCRIPTION (provided by applicant): Diseases associated with the Poxviridae (smallpox, vaccinia and cowpox viruses), and Herpesviridae (HSV-1, HSV-2, HSV-8, VZV, EBV) dsDNA viruses represent major worldwide public health problems. NandN Scientific, Inc. (NandN) is developing a first of its class broad-spectrum orally bioavailable antiviral drug, N- methanocarbathymidine (N-MCT), which has exhibited potent activity against herpes and pox viruses and drug-resistant variants in vivo at doses that are non-cytotoxic in mice, rats, guinea pigs and dogs, even at doses 1000-fold higher than the therapeutic dose. These unique pharmacological characteristics suggest that N-MCT will be an ideal candidate for commercial development upon completing pre-IND studies and clinical trials. This Phase II SBIR proposal will help significantly to advance the development of N-MCT towards clinical testing. Herpes Simplex Virus (HSV) infection is a chronic disease that affects over 1 billion people worldwide, with distinct diseasesymptoms for each variant. Infections are commonly manifested as oral HSV-1 and HSV-2 infections, genital HSV-2 infection and HSV-8 infection in Kaposi's sarcoma, which are prevalent in sexually transmitted diseases and immunosuppressed patients. There are500,000 new HSV-2 cases annually in the USA, and account for 75% of neonatal infections. HSV-1 infects between 20-40% of the adult population age 12 and over, and is manifested by recurrent facial cold sores that are treated predominantly with OTC remedies with limited efficacy. In children lt 14 years of age, as many as 35% have serologic evidence of HSV- 1 infection. To address the public health issues associated with HSV and a major commercial market, NandN proposes to develop N-MCT for the treatment and prophylaxis of genital HSV-2 infection, including neonatal infections, for which the current worldwide market is in excess of 2 billion. Current pre-IND studies of N-MCT conducted during the Phase I SBIR grant have demonstrated that N-MCT has several unique characteristics that make it particularly valuable for commercial development. These include: 1) Cytotoxicity only in HSV-infected cells 2) HSV-tk dependant antiviral activity 3) Activity against acyclovir (ACV)-resistant HSV 4) Activity against HSV-1, HSV-2, HSV-8, vaccinia and cowpox viruses 5) Greater potency than ACV across all doses 6) Activity against genital, neonatal and encephalitic HSV-2 infection, and activity against neonatal infection, even when administered 3 days post-infection, in contrast to the lack of activity of ACV 7) No cytotoxicity in mice, rats, guinea pigs and dogs at doses 1000-fold greater than the therapeutic dose 8) High oral bioavailability (80-90%) in mice, rats and dogs 9) Crosses the blood-brain barrier to eliminate HSV-2 encephalitis in mice, in contrast to a lack of efficacy f ACV 10) No toxicity in dogs administered N-MCT orally on a daily 14-day repeat dose schedule with a 14- day recovery period. 11) High drug stability at room temperature over one year with no decomposition SPECIFIC AIMS NandN proposes to develop the first of its class antiviral drug, N-MCT, for the treatment of HSV-2, including ACV- resistant variants. In the Phase I SBIR grant, NandN completed dose-range finding, 7-day acute toxicity testing in rats and dogs, PK studies in rats and dogs, as well as a 14-day repeat-dose toxicity and toxicokinetic study in dogs, including a cardiovascular assessment. NandN also completed efficacy studies in mice and guinea pigs to evaluate N-MCT against genital HSV-2and neonatal and encephalitic infections, respectively. In this Phase II application, NandN proposes to complete an additional efficacy study in a genital HSV-2 guinea pig model resembling the human disease. In addition, we plan to complete the remainingpreclinical toxicity studies, drug formulation and stability studies, plasma protein binding and metabolism and the synthesis of additional quantities of non- GMP and GMP N-MCT to advance N-MCT to clinical testing as a drug for the treatment of genital, neonatal and encephalitic HSV-2 infections. Specific Aim #1: To obtain additional preclinical efficacy data for N-MCT in a genital HSV-2 guinea pig model. Specific Aim #2: To synthesize sufficient non-GMP and GMP N-MCT for completion of preclinical studies,and formulation and stability studies, respectively. Specific Aim #3: To complete preclinical toxicology and toxicokinetic studies of N-MCT sufficient for filing an IND with the FDA. Formulation studies will define the optimal formulation for a confirmatory PK study in dogs. These studies will allow filing an IND application for the eventual initiation of Phase I clinical trials to determine the maximum tolerated dose, side effects, bioavailability, pharmacokinetics and the starting doses for Phase IIA clinical trials in patients with genital HSV-2 infections. PUBLIC HEALTH RELEVANCE: Diseases associated with Poxviridae (smallpox, vaccinia and cowpox viruses, and Herpesviridae (HSV-1, HSV-2, HSV-8, VZV, EBV) viruses represent major worldwide public health problems. NandN Scientific, Inc. is developing the first of its class broad-spectrum orally bioavailable antiviral drug, N-methanocarbathymidine (N- MCT), which has exhibited potent activity against herpes and pox viruses and drug-resistant variants in vivo at doses that are non-cytotoxic in mice, rats, guinea pigs and dogs, even at doses 1000-fold higher than the therapeutic dose. These unique pharmacological characteristics suggest that N-MCT will be an ideal candidate for commercial developmentthrough further preclinical studies that lead to an IND application and clinical trials. This Phase II SBIR proposal will help to advance N-MCT towards Phase I clinical testing by completing pre-IND requirements and additional efficacy studies in animals for the eventual treatment of genital and neonatal HSV-2 infections.

Principal Investigator:

Aquilur Rahman
301-250-7573
arahman@nnscientific.com

Business Contact:

Robert I. Glaxer
202-687-8324
riglazer@nnscientific.com
Small Business Information at Submission:

NANDN SCIENTIFIC, INC.
10521 ALLOWAY DRIVE POTOMAC, MD -

EIN/Tax ID: 136441629
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No